StockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)

StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report report published on Friday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $6.00 price target on shares of Arcadia Biosciences in a research note on Wednesday, August 21st.

Arcadia Biosciences Stock Down 0.3 %

RKDA stock opened at $2.92 on Friday. The company has a market cap of $3.98 million, a PE ratio of -0.57 and a beta of 1.34. Arcadia Biosciences has a 52 week low of $1.85 and a 52 week high of $4.19. The business has a 50-day simple moving average of $2.84 and a 200 day simple moving average of $2.68.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($0.49). The firm had revenue of $1.31 million for the quarter, compared to analyst estimates of $0.95 million. Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. During the same quarter in the prior year, the business posted ($2.64) EPS. On average, analysts anticipate that Arcadia Biosciences will post -1.7 EPS for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.